who medicines strategy - libdoc.who.int - World Health Organization
who medicines strategy - libdoc.who.int - World Health Organization who medicines strategy - libdoc.who.int - World Health Organization
WHO MEDICINES STRATEGY 2004-2007 | 22WHO MEDICINES STRATEGY 2004-2007SUMMARY TABLE OF PLANNING ELEMENTSOBJECTIVES COMPONENTS EXPECTED OUTCOMES IN COUNTRIESPOLICY1.1 Medicines policies developed, updated and implementedCommitment among1taking into consideration health, development, and intersectoralImplementation and monitoring of policiesall stakeholders tomedicines policies1.2 Implementation of medicines policy regularly monitored andmedicines policiesAdvocate and support theevaluatedbased on the essential implementation and monitoring of1.3 Public health aspects protected in the negotiation andmedicines concept, medicines policies based on theimplementation of international, regional, and bilateral tradeand to coordinated concept of essential medicines.agreementsimplementation, Monitor the impact of trademonitoring and agreements on access to quality1.4 Human resources capacity increased in the pharmaceuticalsectorevaluation of policies. essential medicines. Build capacityin the pharmaceutical sector. 1.5 Promotion of innovation based on public health needs,especially for neglected diseasesACCESSEquitable financing,affordability anddelivery of essentialmedicines in linewith MillenniumDevelopment Goals,Target 17.2Traditional medicine andcomplementary and alternativemedicineAdequate support provided tocountries to promote the safety,efficacy, quality, and sounduse of traditional medicine andcomplementary and alternativemedicine.3Fair financing mechanisms andaffordability of essential medicinesGuidance provided on financingthe supply and increasing theaffordability of essential medicinesin both the public and privatesectors.4Medicines supply systemsEfficient and secure systems formedicines supply promoted forboth the public and private sectors,in order to ensure continuousavailability of essential medicines.1.6 Gender perspectives introduced in the implementation ofmedicines policies1.7 Access to essential medicines recognized as a human right1.8 Ethical practices promoted and anti-corruption measuresidentified and implemented in the pharmaceutical sector2.1 TM/CAM integrated into national health care systems whereappropriate2.2 Safety, efficacy, and quality of TM/CAM enhanced2.3 Availability and affordability of TM/CAM enhanced2.4 Rational use of TM/CAM by providers and consumers promoted3.1 Access to essential medicines improved, including medicinesfor HIV/AIDS, malaria , TB, childhood illnesses andnoncommunicable diseases3.2 Increased public funding of medicines promoted along withcost containment mechanisms3.3 Increased access to medicines through development assistance,including the Global Fund3.4 Medicines benefits promoted within social health insurance andpre-payment schemes3.5 Medicine pricing policies and exchange of price informationpromoted3.6 Competition and generic policies implemented4.1 Supply systems assessed and successful strategies promoted4.2 Medicines supply management improved4.3 Local production assessed and strengthened, as appropriate andfeasible4.4 Good procurement practices and purchasing efficiencyimproved4.5 Public-interest NGOs included in national medicine supplystrategies, where appropriate
MEDICINES AND PUBLIC HEALTH | 23OBJECTIVES COMPONENTS EXPECTED OUTCOMES IN COUNTRIESQUALITY5ANDNorms and standards forSAFETYpharmaceuticalsGlobal norms, standard, and 5.3 Pharmaceutical specifications and reference materialsThe quality, safetydeveloped and maintainedguidelines for the quality, safety,and efficacy of alland efficacy of medicinesmedicines assured strengthened and promoted.by strengthening andputting into practiceregulatory and qualityassurance standardsRATIONALUSETherapeutically soundand cost-effective useof medicines by healthprofessionals andconsumers6Medicines regulation and qualityassurance systemsInstruments for effective drugregulation and quality assurancesystems promoted in order tostrengthen national drug regulatoryauthorities.7Rational use by health professionalsand consumersAwareness raising and guidance oncost-effective and rational use ofmedicines promoted, with a view toimproving medicines use by healthprofessionals and consumers.5.1 Pharmaceutical norms, standards, and guidelines developed orupdated5.2 Medicines nomenclatures and classification efforts continued5.4 Balance between abuse prevention and appropriate access topsychoactive substances achieved6.1 Medicines regulation effectively implemented and monitored6.2 Information management and exchange systems promoted6.3 Good practices in medicine regulation and quality assurancesystems promoted6.4 Post-marketing surveillance of medicine safety maintained andstrengthened6.5 Use of substandard and counterfeit medicines reduced6.6 Prequalification of products and manufacturers of medicinesfor priority diseases and quality control laboratories, asappropriate, through procedures and guidelines appropriate forthis activity6.7 Safety of new priority and neglected medicines enhanced6.8 Regulatory harmonization monitored and promoted, asappropriate, and networking initiatives developed7.1 Rational use of medicines by health professionals andconsumers advocated7.2 Essential medicines list, clinical guidelines, and formularyprocess developed and promoted7.3 Independent and reliable medicines information identifieddisseminated and promoted7.4 Responsible ethical medicines promotion for healthprofessionals and consumers encouraged7.5 Consumer education enhanced7.6 Drug and therapeutics committees promoted at institutional anddistrict/national levels7.7 Training in good prescribing and dispensing practices promoted7.8 Practical approaches to contain antimicrobial resistancedeveloped based on the WHO Global Strategy to containAntimicrobial Resistance7.9 Identification and promotion of cost-effective strategies topromote rational use of medicines
- Page 10 and 11: WHO MEDICINES STRATEGY 2004-2007 |x
- Page 12 and 13: WHO MEDICINES STRATEGY 2004-2007 |x
- Page 14 and 15: WHO MEDICINES STRATEGY 2004-2007 |
- Page 23: MEDICINESAND PUBLIC HEALTH
- Page 26 and 27: WHO MEDICINES STRATEGY 2004-2007 |
- Page 28 and 29: WHO MEDICINES STRATEGY 2004-2007 |
- Page 30 and 31: WHO MEDICINES STRATEGY 2004-2007 |
- Page 32 and 33: WHO MEDICINES STRATEGY 2004-2007 |
- Page 36 and 37: WHO MEDICINES STRATEGY 2004-2007 |
- Page 38 and 39: WHO MEDICINES STRATEGY 2004-2007 |
- Page 40 and 41: WHO MEDICINES STRATEGY 2004-2007 |
- Page 42 and 43: WHO MEDICINES STRATEGY 2004-2007 |
- Page 44 and 45: WHO MEDICINES STRATEGY 2004-2007 |
- Page 46 and 47: WHO MEDICINES STRATEGY 2004-2007 |
- Page 48 and 49: WHO MEDICINES STRATEGY 2004-2007 |
- Page 50 and 51: WHO MEDICINES STRATEGY 2004-2007 |
- Page 52 and 53: WHO MEDICINES STRATEGY 2004-2007 |
- Page 54 and 55: WHO MEDICINES STRATEGY 2004-2007 |
- Page 56 and 57: WHO MEDICINES STRATEGY 2004-2007 |
- Page 58 and 59: WHO MEDICINES STRATEGY 2004-2007 |
- Page 60 and 61: WHO MEDICINES STRATEGY 2004-2007 |
- Page 62 and 63: WHO MEDICINES STRATEGY 2004-2007 |
- Page 64 and 65: WHO MEDICINES STRATEGY 2004-2007 |
- Page 66 and 67: WHO MEDICINES STRATEGY 2004-2007 |
- Page 68 and 69: WHO MEDICINES STRATEGY 2004-2007 |
- Page 70 and 71: WHO MEDICINES STRATEGY 2004-2007 |
- Page 72 and 73: WHO MEDICINES STRATEGY 2004-2007 |
- Page 74 and 75: WHO MEDICINES STRATEGY 2004-2007 |
- Page 76 and 77: WHO MEDICINES STRATEGY 2004-2007 |
- Page 78 and 79: WHO MEDICINES STRATEGY 2004-2007 |
- Page 80 and 81: WHO MEDICINES STRATEGY 2004-2007 |
- Page 82 and 83: WHO MEDICINES STRATEGY 2004-2007 |
WHO MEDICINES STRATEGY 2004-2007 | 22WHO MEDICINES STRATEGY 2004-2007SUMMARY TABLE OF PLANNING ELEMENTSOBJECTIVES COMPONENTS EXPECTED OUTCOMES IN COUNTRIESPOLICY1.1 Medicines policies developed, updated and implementedCommitment among1taking <strong>int</strong>o consideration health, development, and <strong>int</strong>ersectoralImplementation and monitoring of policiesall stakeholders to<strong>medicines</strong> policies1.2 Implementation of <strong>medicines</strong> policy regularly monitored and<strong>medicines</strong> policiesAdvocate and support theevaluatedbased on the essential implementation and monitoring of1.3 Public health aspects protected in the negotiation and<strong>medicines</strong> concept, <strong>medicines</strong> policies based on theimplementation of <strong>int</strong>ernational, regional, and bilateral tradeand to coordinated concept of essential <strong>medicines</strong>.agreementsimplementation, Monitor the impact of trademonitoring and agreements on access to quality1.4 Human resources capacity increased in the pharmaceuticalsectorevaluation of policies. essential <strong>medicines</strong>. Build capacityin the pharmaceutical sector. 1.5 Promotion of innovation based on public health needs,especially for neglected diseasesACCESSEquitable financing,affordability anddelivery of essential<strong>medicines</strong> in linewith MillenniumDevelopment Goals,Target 17.2Traditional medicine andcomplementary and alternativemedicineAdequate support provided tocountries to promote the safety,efficacy, quality, and sounduse of traditional medicine andcomplementary and alternativemedicine.3Fair financing mechanisms andaffordability of essential <strong>medicines</strong>Guidance provided on financingthe supply and increasing theaffordability of essential <strong>medicines</strong>in both the public and privatesectors.4Medicines supply systemsEfficient and secure systems for<strong>medicines</strong> supply promoted forboth the public and private sectors,in order to ensure continuousavailability of essential <strong>medicines</strong>.1.6 Gender perspectives <strong>int</strong>roduced in the implementation of<strong>medicines</strong> policies1.7 Access to essential <strong>medicines</strong> recognized as a human right1.8 Ethical practices promoted and anti-corruption measuresidentified and implemented in the pharmaceutical sector2.1 TM/CAM <strong>int</strong>egrated <strong>int</strong>o national health care systems whereappropriate2.2 Safety, efficacy, and quality of TM/CAM enhanced2.3 Availability and affordability of TM/CAM enhanced2.4 Rational use of TM/CAM by providers and consumers promoted3.1 Access to essential <strong>medicines</strong> improved, including <strong>medicines</strong>for HIV/AIDS, malaria , TB, childhood illnesses andnoncommunicable diseases3.2 Increased public funding of <strong>medicines</strong> promoted along withcost containment mechanisms3.3 Increased access to <strong>medicines</strong> through development assistance,including the Global Fund3.4 Medicines benefits promoted within social health insurance andpre-payment schemes3.5 Medicine pricing policies and exchange of price informationpromoted3.6 Competition and generic policies implemented4.1 Supply systems assessed and successful strategies promoted4.2 Medicines supply management improved4.3 Local production assessed and strengthened, as appropriate andfeasible4.4 Good procurement practices and purchasing efficiencyimproved4.5 Public-<strong>int</strong>erest NGOs included in national medicine supplystrategies, where appropriate
Change language